DNA repair biomarkers to guide usage of combined PARP inhibitors and chemotherapy: A meta-analysis and systematic review
Purpose: The addition of PARP inhibitors to chemotherapy has been assessed in > 80 clinical trials across multiple malignancies, on the premise that PARP inhibitors will increase chemotherapy effectiveness regardless of whether cancers have underlying disruption of DNA repair pathways. Consequent...
Saved in:
Main Authors: | Zoe Phan (Author), Caroline E. Ford (Author), C. Elizabeth Caldon (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2023-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PARP inhibitors combined with radiotherapy: are we ready?
by: Chen Sun, et al.
Published: (2023) -
Expanding the Use of PARP Inhibitors as Monotherapy and in Combination in Triple-Negative Breast Cancer
by: Mariya Yordanova, et al.
Published: (2021) -
Efficacy of a platinum-based chemotherapy rechallenge for platinum-sensitive recurrence after PARP inhibitor maintenance
by: Takehiro Nakao, et al.
Published: (2024) -
Resistance to PARP-inhibitors in Cancer Therapy
by: Alicia eMontoni, et al.
Published: (2013) -
PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies
by: Nannan Wang, et al.
Published: (2022)